Compare AGNC Investment Corp (AGNC) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AGNC Investment Corp vs Vertex Pharmaceuticals Incorporated — how do they compare? AGNC Investment Corp trades at $10.9 (market cap $12.91B), while Vertex Pharmaceuticals Incorporated trades at $528.16 (market cap $134.25B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 10.4× AGNC Investment Corp's market cap, and AGNC Investment Corp pays a 13.22% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| AGNC | VRTX | |
|---|---|---|
Market Cap | $12.91B | $134.25B |
Sector | Financials | Health |
52-Week High | $12.17 | $529.65 |
52-Week Low | $9.46 | $376.62 |
Dividend Yield | 13.22% | — |
Enterprise Value | — | $128.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AGNC Investment Corp. trades at $10.76, down 0.74% on the day, with a bullish technical signal from moving averages and a neutral stance from oscillators. The mortgage REIT reported strong profitability with a net income margin of 94.38% and ROE of 21.67% for 2025, while recent earnings beat expectations in Q1 and Q2 2026. Analysts maintain a consensus price target of $11.30, with 31% recommending Buy, though the majority (60%) suggest Hold.
AGNC offers a high dividend yield, supported by consistent payouts, but faces risks from interest rate sensitivity and leveraged mortgage securities. Upside potential exists if stable spreads persist, yet the stock's valuation above book value requires careful monitoring of portfolio performance and macroeconomic conditions.
Vertex Pharmaceuticals (VRTX) trades at $523.91, up 5.61% with strong technical momentum and bullish moving averages. The company reported Q2 2026 revenue growth of 12% to $3.3 billion, beating expectations despite an EPS miss, and raised its full-year 2026 revenue guidance. Valuation metrics show a P/E of 30.85 and P/S of 10.78, while maintaining robust profitability with 86% gross margins and 35% net income margins.
Outlook remains positive with analyst consensus strongly bullish (84% buy ratings) and a $534.25 price target. Key risks include execution on newer product launches and competitive pressures in cystic fibrosis treatments. The stock's current momentum suggests continued upside potential, though RSI levels indicate potential near-term overbought conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AGNC Investment Corp
AGNC Investment Corp is a real estate investment trust that invests in agency residential mortgage-backed securities. The firm's asset portfolio is comprised of residential mortgage pass-through securities and collateralized mortgage obligations for which the principal and interest payments are guaranteed by a U.S. Government-sponsored enterprise, such as the Federal National Mortgage Association and the Federal Home Loan Mortgage Corporation, or by a U.S. Government agency, such as the Government National Mortgage Association. It also invests in other types of mortgage and mortgage-related residential and commercial mortgage-backed securities or other investments in or related to, the housing, mortgage or real estate markets.
Read more on AGNC →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
